Tool · updated 17 May 2026

PCOS / PMOS annual check-up schedule

Which blood tests should you have with PMOS / PCOS — and how often? Answer 6 questions about your profile to generate a personalised monitoring plan of 8-15 recommended tests, complete with clinical rationale, guideline sources, PDF export and iCal download.

Information tool, not a prescription. This schedule is based on 2023-2026 international guidelines (Monash, ESHRE, Endocrine Society, NICE). It does not replace a consultation with your doctor, who will adapt monitoring to your full clinical picture.

Why a structured annual monitoring plan matters

PMOS (Polycystic Metabolic-Ovarian Syndrome) is a long-term condition. It does not resolve at diagnosis — it evolves across decades, with changing metabolic, hormonal and cardiovascular risk depending on age, weight, treatment and reproductive status. Yet most patients report leaving their GP's office without a clear monitoring plan.

The 2023 Monash international evidence-based guideline and the ESHRE 2023 guideline both recommend structured annual metabolic screening from diagnosis, regardless of weight or symptom severity. Many patients with a "normal" BMI carry silent insulin resistance, dyslipidaemia or early hypertension that only structured testing will detect.

A monitoring plan also helps you have a more productive conversation with your doctor. Arriving with a printed schedule — showing what you have had tested, what is overdue, and the clinical rationale — changes the dynamic of the appointment. The PDF export from this tool is designed for exactly that purpose.

Finally, early detection matters. T2 diabetes risk is 4× higher in PMOS. Endometrial hyperplasia risk is 2.7× higher with chronic amenorrhoea. Cardiovascular risk accumulates silently through the 30s and 40s. Annual testing catches these trajectories early — when intervention is most effective.

The 7 categories of PMOS monitoring

The schedule groups recommended tests into 7 clinical categories. Each reflects a distinct dimension of PMOS health risk.

1. Metabolic Panel

Fasting glucose, HbA1c, lipid panel, vitamin D, ferritin and HOMA-IR (insulin resistance index). This is the core of annual PMOS monitoring. Dyslipidaemia affects up to 70% of patients; glucose impairment is common even at normal weight. See our HOMA-IR calculator for the insulin resistance calculation.

2. Hormonal Panel

Testosterone (total + free), SHBG and AMH. The androgens confirm and monitor hyperandrogenism — the "H" in most PMOS phenotypes. AMH tracks ovarian reserve and is elevated in most PMOS patients; it is a diagnostic marker under the updated 2023 criteria. TSH excludes thyroid disease, which is 3× more common in PMOS.

3. Imaging

Transvaginal pelvic ultrasound every 2-3 years (or sooner if symptomatic). Monitors ovarian morphology, follicle count and endometrial thickness. Post-menopause, a DEXA scan is added to monitor bone density, and routine cancer screening (mammogram, cervical smear) is flagged as a reminder.

4. Cardiovascular

Blood pressure, waist circumference, resting ECG (for high-risk profiles) and cardiovascular risk score (QRISK3 / SCORE2). PMOS patients have 1.5× higher hypertension risk and 2× higher metabolic syndrome risk. Cardiovascular monitoring intensifies from age 35 and becomes central after 45.

5. Mental Health

Annual PHQ-9 (depression) and GAD-7 (anxiety) screening. Anxiety is 3.5× and depression 3.8× more prevalent in PMOS — yet mental health is systematically under-screened in routine appointments. The Monash 2023 guideline explicitly recommends psychological assessment at every annual review. See our page on PCOS and mental health.

6. Fertility

Triggered when a pregnancy project is indicated. Includes a complete fertility panel (AMH, FSH/LH, prolactin, ultrasound) and partner semen analysis (male factor accounts for 30% of infertility cases). Pre-conception planning 1-3 years ahead uses AMH to anticipate ovarian reserve. See our page on PCOS fertility.

7. Endometrial Health

Endometrial thickness monitoring for patients aged 25-54 with chronic oligo- or amenorrhoea. Chronic anovulation leads to unopposed oestrogen exposure, increasing endometrial hyperplasia and cancer risk by 2.7×. The RCOG recommends inducing a withdrawal bleed every 3 months and monitoring thickness via ultrasound if amenorrhoea persists.

Which tests are NHS-covered / insurance-covered

Coverage varies significantly by country and clinical context. The following is a general guide — always confirm with your GP or insurer before booking.

Test	NHS (UK)	US Insurance	Notes
Fasting glucose + HbA1c	Yes	Usually yes	Standard metabolic screen, widely covered
Lipid panel	Yes	Usually yes	Standard cardiovascular risk screen
TSH	Yes	Usually yes	Routine exclusion test
Testosterone + SHBG	Yes (via GP)	Yes with PCOS code	Free testosterone may require specialist referral
Fasting insulin (HOMA-IR)	Not routinely	Varies	Often requires private lab in UK; request explicitly
AMH	Specialist only	With fertility indication	Rarely covered without referral
Pelvic ultrasound	Yes	Usually yes	Transvaginal preferred; may need referral
Vitamin D + ferritin	Yes (symptomatic)	Varies	Routine annual test if history of deficiency

Always quote your PCOS / PMOS diagnosis (ICD-10: E28.2) on test requests. Coverage improves significantly when the clinical indication is documented.

How to discuss your results with your doctor

Receiving a lab report without context is stressful and rarely actionable. Here are practical steps for turning results into a productive conversation.

Print or save your schedule. Use the PDF export above to bring a one-page summary to your appointment. It lists each recommended test with frequency and clinical rationale. Your doctor can tick off what has been done and order what is overdue.
Track trends, not single values. HOMA-IR, testosterone and lipid values fluctuate. A single abnormal result is less meaningful than a trend over 2-3 years. Keep a copy of each year's results to compare.
Ask about thresholds specific to your lab. HOMA-IR thresholds vary by laboratory and insulin assay. Ask your doctor which threshold applies to your lab's insulin measurement method. The same applies to testosterone and AMH reference ranges.
Request the numerical value, not just "normal". A glucose of 5.4 mmol/L and 6.8 mmol/L are both "below 7" but clinically very different. Always ask for the figure to track over time.
Mention treatments candidly. Some supplements (inositol, berberine, vitamin D) affect metabolic markers. Some medications (spironolactone, COC) mask androgen levels. Your doctor needs to know what you are taking to interpret results correctly.

For a structured appointment template, see our My appointment summary tool and understanding PCOS blood tests guide.

Common monitoring mistakes in PMOS

These are the most frequent gaps identified in PMOS follow-up, based on patient reports and clinical audits.

1
Stopping metabolic tests after symptoms improve. PMOS is not cured by weight loss or COC treatment. Metabolic risk persists and may re-emerge — particularly post-partum or post-menopause. Annual screening should continue regardless of perceived stability.
2
Skipping insulin resistance testing in lean patients. "I have a normal BMI, so I don't need HOMA-IR" is a common misconception. Lean insulin resistance is real and affects treatment choice. Phenotypes A and B especially carry this risk — see our lean PCOS page.
3
Not monitoring endometrium with long gaps between periods. If you go 3+ months without a period and have no monitoring in place, you are missing a key safety check. Progestogen every 3 months and annual ultrasound endometrial thickness are the standard recommendation.
4
Not checking B12 on long-term Metformin. Metformin reduces B12 absorption in 10-30% of patients after 2 years of use. B12 deficiency causes fatigue, cognitive symptoms and peripheral neuropathy — often attributed to PMOS or depression. Annual B12 check is a simple, inexpensive safety measure.
5
No mental health screening at annual review. Anxiety and depression are clinical features of PMOS, not just side-effects. PHQ-9 and GAD-7 take 3 minutes to complete and should be part of every annual review. Most patients with PMOS-related depression are not diagnosed until years after onset.

HOMA-IR calculator Symptom checker Lean PCOS Lab tests guide

Frequently asked questions

How often should I have blood tests with PMOS?+

The 2023 Monash and ESHRE guidelines recommend annual metabolic screening (fasting glucose, HbA1c, lipid panel) for all PMOS patients regardless of weight or symptoms. Hormonal panels are typically repeated every 2-3 years unless something changes clinically. Thyroid (TSH) every 2-3 years. Mental health screening once a year with your GP. The exact frequency depends on your age, BMI, treatments and risk profile — the tool above calculates a personalised schedule.

Which tests are covered by NHS / insurance?+

In the UK, most metabolic tests (fasting glucose, HbA1c, lipid panel, TSH) and hormone panels are available on NHS when prescribed by a GP or specialist for a documented condition. Fasting insulin for HOMA-IR calculation is not routinely available on NHS and may require a private lab. In the US, coverage depends on your insurer and the documented indication — having a PCOS/PMOS diagnosis code (ICD-10: E28.2) on the order usually triggers coverage for standard metabolic and hormonal tests. AMH is often not covered without a fertility indication. Always check with your GP or insurer before booking.

Do I need a HOMA-IR test if I'm a healthy weight?+

Yes, particularly for phenotypes A, B and unknown diagnoses. Lean insulin resistance (normal BMI with elevated HOMA-IR) affects roughly 20-30% of lean PMOS patients and is frequently missed. Insulin resistance at normal weight still carries metabolic and fertility consequences. The Endocrine Society 2026 guidelines flag fasting insulin + glucose as useful even in lean PMOS. See our HOMA-IR calculator for the calculation and thresholds.

Does the check-up schedule change after 40?+

Yes, meaningfully. From age 35, blood pressure and waist circumference monitoring becomes twice-yearly due to 1.5× higher hypertension risk. From 45, a cardiovascular risk score (QRISK3 or SCORE2) is added every 5 years, and an ECG is recommended every 2 years for patients with family CVD history. Post-menopause (55+), DEXA bone density scan and routine cancer screening are added. The transition out of reproductive years also modifies the fertility and endometrial monitoring components.

Do I need endometrial monitoring with irregular periods?+

Yes, if you have gone more than 3 consecutive months without a period. Chronic oligo-amenorrhoea increases endometrial hyperplasia risk by 2.7× due to unopposed oestrogen. The RCOG recommends inducing a withdrawal bleed with progestogen at least every 3 months, and monitoring endometrial thickness via transvaginal ultrasound annually if amenorrhoea persists. This applies most directly to patients aged 25-54. If you have concerns, discuss with your gynaecologist — do not wait for symptoms.

Can I share this schedule with my doctor?+

Yes, and we encourage it. The PDF export includes your full profile (age bracket, phenotype, BMI range, treatments) and the clinical rationale for each test with guideline sources. You can print it or share it digitally. It is designed to facilitate a conversation with your GP or specialist — not to replace one. Your doctor may adjust the schedule based on your full clinical picture.

Information tool based on 2023-2026 guidelines (Monash, ESHRE, Endocrine Society, NICE, ESC). Does not constitute a prescription or personalised medical advice. Always discuss your monitoring plan with your GP or specialist.